Biotech

Startups News

Biotech Startups Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech

Top news of the week: 01.12.2021.

Biotechnology
Antibody
Vaccination
Economics
Immunohistochemistry
Myocardial infarction

Startups

@TheEconomist shared
On Nov 25, 2021
The venture-capital industry is being supersized. There are risks—but it is also a chance to make the industry bigger and better. Our cover this week https://t.co/r7BPIeqIMf https://t.co/3fRKfksj5s
Open
Adventure capitalism

Adventure capitalism

The venture-capital industry is being supersized. Good

@matthewherper shared
On Nov 26, 2021
'Start at the top': Women in biotech on how to break down barriers https://t.co/fIc85hjx5c
Open
‘Start at the top’: Women in biotech on how to break down barriers in the industry

‘Start at the top’: Women in biotech on how to break down barriers in the industry

Women leaders in biotech said the industry has made significant progress toward gender equity, but there's still far more work to be done.

@Forbes shared
On Nov 28, 2021
Squid Game, Ted Lasso, And Unicorn Fatigue: Top 10 Healthcare Industry Predictions For 2022 https://t.co/HrOlx9srHL https://t.co/lYTvQc8pwX
Open
Squid Game, Ted Lasso, And Unicorn Fatigue: Top 10 Healthcare Industry Predictions For 2022

Squid Game, Ted Lasso, And Unicorn Fatigue: Top 10 Healthcare Industry Predictions For 2022

Now, I invite you to put your feet up, ignore the soreness in your arm from your booster shot, and enjoy my Top 10 Predictions For The Healthcare Industry In 2022.

@FierceBiotech shared
On Dec 1, 2021
Neither company has disclosed the terms of the deal. Origimm kept a fairly low profile over its nine-year history, disclosing a series A financing in 2016, without revealing the size of the round, and additional cash from an Austrian funding scheme in 2018 https://t.co/UOBgYYlclT
Open
Sanofi snaps up Origimm for early-phase acne vaccine, opening new front in mRNA strategy

Sanofi snaps up Origimm for early-phase acne vaccine, opening new front in mRNA strategy

Sanofi is adding another thread to its mRNA strategy. Having already bagged Translate Bio’s mRNA platform, Sanofi is now snapping up Origimm Biotechnology to land a therapeutic acne vaccine ...

@BusinessInsider shared
On Nov 29, 2021
RT @HealthInsider: Omicron has drug companies preparing for the worst. Here are their plans to counterattack the newest COVID-19 variant. https://t.co/AFQXo8Gk0x
Open
Omicron has drug companies preparing for the worst. Here are their plans to counterattack the newest COVID-19 variant.

Omicron has drug companies preparing for the worst. Here are their plans to counterattack the newest COVID-19 variant.

Experts fear that the newest variant may make vaccines and therapies less effective. "On the face of it, it looks pretty gnarly," one said.

@BillGates shared
On Nov 29, 2021
The @gatesfoundation is supporting GIISER which is working to increase the in-country capacity for rapid evaluation of variants on the African continent. This will help us better understand variants of concern and how the current vaccines may perform. https://t.co/yz9XWS4LWH
Open
Global Immunology and Immune Sequencing for Epidemic Response (GIISER) Sites in Africa

Global Immunology and Immune Sequencing for Epidemic Response (GIISER) Sites in Africa

Overview The emerging SARS-COV-2 variants of concern (VOC) demonstrate the urgent need for local scientific communities to have the capacity to rapidly detect and evaluate the immunological ...

@BentheFidler shared
On Nov 29, 2021
RT @ByJonGardner: Today, take a few minutes to read @BentheFidler 's deep and well-researched profile of Verve Therapeutics' founder Sek Kathiresan. You'll be glad you did. https://t.co/41HfxenXaL
Open
Heart attacks struck Sek Kathiresan's family. He's devoted his life to stopping them.

Heart attacks struck Sek Kathiresan's family. He's devoted his life to stopping them.

After several family members had early heart attacks, Kathiresan vowed to understand why they happen. His research journey has changed medical practice and led to a new biotech startup, ...

@zbiotech shared
On Nov 26, 2021
RT @bio_clouseau: $MRK molnupiravir RRR down to 30% at updated analysis from 48% @ interim https://t.co/GvyosBO2Ra
Open
Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir

Read more: Startups
weekly 01.12.2021
View archives
Back to home

Subscribe to Biotech - Startups.

Avoid an information overload and get the most trusted industry news hand-picked by the top Experts. Sign up for the weekly Biotech - Startups.
Privacy Policy

Sign up for the weekly Biotech - Startups newsletter

Never again miss anything or anyone that matter in Biotech

Sign up and receive the Biotech - Startups weekly email newsletter directly to your inbox. Make more informed business decisions based on insight for the most trusted industry experts, faster.
Privacy Policy